Polycystic ovary syndrome (PCOS) – role of chronic inflammation in the expression of dysmetabolic phenotype

Metabolic hormonal alterations in functional hypothalamic amenorrhea and anovulation associated with Polycystic ovary syndrome

“…Adolescent girls with PCOS have been effectively treated for this neuroendocrine anomaly using the androgen receptor blocker, flutamide, highlighting the role of excess androgen in dampening hypothalamic feedback inhibition and consequently increasing GnRH pulsatility during puberty. However, not all teenage females with PCOS exhibit decreased hypothalamic feedback inhibition in response to androgen excess, suggesting potential variability influenced by the duration of androgen exposure or genetic predisposition [66]. Moreover, women with PCOS manifest other neuroendocrine abnormalities, including an amplified response to GnRH and a LH release pattern resembling that of individuals with congenital adrenal virilizing illnesses rather than typical women without PCOS.…”

“…Efforts to improve awareness, education, and early detection of these conditions are essential for timely intervention and management [67]. Research into the underlying mechanisms, risk factors, and treatment modalities for FHA and PCOS continues to advance, with a focus on personalized approaches tailored to individual patient needs [66]. Moreover, initiatives to address the broader socio-economic and cultural factors influencing women's health, such as access to healthcare services, nutritional support, and mental health resources, are critical for mitigating the global impact of FHA and PCOS [68].…”